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Background: Stent thrombosis remains among the most feared complications of percutaneous coronary inter-
vention (PCI) with stenting. However, data on its incidence and predictors are sparse and conﬂicting. We
thus aimed to perform a collaborative systematic review on incidence and predictors of stent thrombosis.
Methods: PubMed was systematically searched for eligible studies from the drug-eluting stent (DES) era
(1/2002–12/2010). Studies were selected if including ≥2000 patients undergoing stenting or reporting on
≥25 thromboses. Study features, patient characteristics, and incidence of stent thrombosis were abstracted
and pooled, when appropriate, with random-effect methods (point estimate [95% conﬁdence intervals]),
and consistency of predictors was formally appraised.
Results: A total of 30 studies were identiﬁed (221,066 patients, 4276 thromboses), with DES used in 87%.
After a median of 22 months, deﬁnite, probable, or possible stent thrombosis had occurred in 2.4% (2.0%;
2.9%), with acute in 0.4% (0.2%; 0.6%), subacute in 1.1% (1.0%; 1.3%), late in 0.5% (0.4%; 0.6%), and very late
in 0.6% (0.4%; 0.8%). Similar ﬁgures were computed for studies reporting only on DES. From a total of 47
candidate variables, deﬁnite/probable stent thrombosis was more commonly and consistently predicted by
early antiplatelet therapy discontinuation, extent of coronary disease, and stent number/length, with acutergical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy. Tel.: +39
0773 175 72 54.
i-Zoccai).
Ltd. All rights reserved.
576 F. D'Ascenzo et al. / International Journal of Cardiology 167 (2013) 575–584coronary syndrome at admission, diabetes, smoking status, and bifurcation/ostial disease also proving fre-
quent predictors, but less consistently.
Conclusions: Despite numerous possible risk factors, the most common and consistent predictors of stent
thrombosis are early antiplatelet therapy discontinuation, extent of coronary disease, and stent number/
length.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Stent thrombosis is a catastrophic, although relatively uncommon,
complication of percutaneous coronary intervention (PCI) [1,2]. Stent
thrombosis can present as ST-elevation myocardial infarction or
cardiogenic shock in up to 75% and 30% of cases, respectively, with
case fatality reaching 18% during the index hospitalization and 25%
at 1 year [2-8]. Furthermore, up to 39% of patientswith stent thrombo-
sis experience a recurrentmyocardial infarctionwithin the ﬁrstmonth
despite an initially successful repeat PCI [9-11]. These striking data
were among the main reasons for international recommendations
to prolong dual antiplatelet therapy to 12 months or even longer in
those undergoing PCI with drug-eluting stents (DES), especially after
acute coronary syndromes (ACS); for a more selective use of DES,
and to develop more effective antithrombotic agents [12-15].
All physicians taking care of patients who receive coronary stents,
including but not limited to interventional cardiologists, should be
thoroughly knowledgeable of the risk of stent thrombosis, and of pre-
disposing/protective features, which might drive decision-making
before as well as after stenting. However, the evidence base on
stent thrombosis in the current era is fraught with conﬂicting data
on risk and predictors, which remain difﬁcult to overcome without
a systematic and collaborative approach. Stemming from previous
similar endeavors from our research group, we aimed to perform
an international collaborative systematic review and meta-analysis
focusing on incidence and predictors of coronary stent thrombosis
in the DES era.
2. Methods
This work was conducted in keeping with current guidelines, including the recent
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
amendment to the Quality of Reporting of Meta-analyses (QUOROM) statement, as
well as recommendations from The Cochrane Collaboration and Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) [16-19]. The review was also regis-
tered online at its inception on metcardio.org to minimize duplicate efforts [16].
2.1. Search strategy
MEDLINE/PubMed was searched for pertinent articles published in English be-
tween January 2002 (when DES were ﬁrst marketed worldwide) and December 2010
according to the following strategy, in keeping with established methods [20] and
incorporating wild cards (identiﬁed by *): stent* AND thrombosis AND coronary AND
english[lang] AND ("2002"[pdat] : "2010"[pdat]) NOT (review[pt] OR editorial[pt] OR
letter[pt]). We did not search The Cochrane Collaboration CENTRAL database, as it
only includes controlled clinical trials. In addition we avoided EMBASE and articles
published in non-English languages as it is very unlikely that high quality observation-
al studies with ≥2000 patients undergoing stenting or ≥25 stent thromboses were
published in non-English journals not indexed in MEDLINE/PubMed. Nonetheless,
all corresponding authors of shortlisted studies were systematically and repeatedly
queried for additional quantitative details. Concomitantly, they were asked for addi-
tional pertinent studies on the topic, and offered coauthorship in the present work.
2.2. Study selection
Retrieved citations were ﬁrst screened independently by two unblinded reviewers
(GBZ, FDA) at the title and/or abstract level, with divergences resolved after consensus.
If potentially pertinent, they were then appraised as complete reports according to the
following explicit selection criteria, which were piloted over the ﬁrst 5 cases. Inclusion
criteria were (all had to be met for inclusion): (i) human studies, (ii) investigating pa-
tients undergoing PCI with stent, (iii) published between 2002 and 2010, (iv) including
≥2000 patients undergoing stenting or ≥25 stent thromboses (irrespective of the
deﬁnition), and (v) reporting predictors of stent thrombosis obtained throughmultivariate analysis. Exclusion criteria were (any one alone was enough for exclu-
sion): (i) non-human setting, (ii) duplicate reporting (in which case the manuscript
reporting the largest sample of patients with stent thromboses was selected, or if
equal, the study with the largest number of overall patients), or (iii) control group lim-
ited to patients with other kinds of coronary thromboses (i.e. de novo myocardial
infarction).
We a priori chose to discard studies with b2000 patients and b25 stent thrombo-
ses as they were unlikely, given established assumptions of multivariable analysis
methods, to provide valid and robust incidence and prognostic estimates [21].2.3. Data extraction
The following datawere independently abstracted by two unblinded reviewers (GBZ,
FDA) on pre-speciﬁed electronic forms, which were piloted over the ﬁrst 5 cases, with
divergences resolved after consensus. In particular, authors, journal, year of publication,
location of the study group, baseline, angiographic and procedural features, stent throm-
boses (total number and distinguished as deﬁnite, deﬁnite or probable, and acute,
subacute, late and very late according to the Academic Research Consortium [ARC] deﬁni-
tions), and multivariate predictors (estimator, point summary estimate of risk, 95% conﬁ-
dence intervals) [22]. Speciﬁcally, ARC distinguished stent thrombosis as acute (0–24 h
after stenting), subacute (2–30 days), late (31–365 days), or very late (>365 days).More-
over, deﬁnite stent thrombosis was deﬁned as angiographically or pathologically proven
stent thrombosis. Probable stent thrombosiswas deﬁned as any unexplained deathwithin
the ﬁrst 30 days after stenting or, irrespective of time after procedure, any myocardial in-
farction related to documented acute ischemia in the territory of the implanted stent
without angiographic conﬁrmation of stent thrombosis and in the absence of any other
obvious cause. Possible stent thrombosis was deﬁned as any unexplained death from
30 days after stenting until end of follow-up. Data from studies published before the adop-
tion of ARC deﬁnitions were extracted and abstracted in keeping with the deﬁnition used
in each individual study. Thus, angiographically proven thrombosiswas considered equiv-
alent to ARC deﬁnite thrombosis, and clinically adjudicated thrombosis was considered
equivalent to ARC deﬁnite, probable or possible thrombosis. Nonetheless, all correspond-
ing authors of included studies were systematically queried to conﬁrm or disprove
abstracted data. End-points of interest for the present review were the incidence of
stent thrombosis at the different time points as well as multivariable predictors of stent
thrombosis. Given the exploratory yet comprehensive scope of this collaborative review,
no explicit primary end-point was speciﬁed.2.4. Internal validity and quality appraisal
The quality of included studies was independently appraised by two unblinded
reviewers (GBZ, FDA), on pre-speciﬁed electronic forms, which were piloted over the
ﬁrst 5 cases, with divergences resolved after consensus. Modifying the MOOSE item
list in order to take into account the speciﬁc features of included studies [18], we sep-
arately abstracted and appraised study design, setting, data source, and statistical
methods for multivariable analysis, as well as, in keeping with The Cochrane Collabo-
ration approach, the risk of analytical, selection, adjudication, detection, and attrition
bias (expressed as low, moderate, or high risk of bias, as well as incomplete reporting
leading to inability to ascertain the underlying risk of bias).2.5. Data analysis and synthesis
Continuous variables are reported as mean (standard deviation) or median (1st;
3rd quartile). Categorical variables are expressed as n/N (%). Statistical pooling for
incidence estimates was performed according to a random-effect model with generic
inverse-variance weighting, computing risk estimates with 95% conﬁdence intervals,
using RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenha-
gen, Denmark). Conversely, risk estimates were not pooled from individual studies
as this approach would have not been feasible and valid given the high risk for pub-
lication bias). We instead adopted Ross et al.'s approach [23], and appraised the
prevalence of studies in which a given predictor was proven signiﬁcantly and inde-
pendently associated with the outcome of interest. Small study bias was appraised
by graphical inspection of funnel plots. Hypothesis testing for superiority was set
at the two-tailed 0.05 level. Hypothesis testing for statistical homogeneity was set
at the two-tailed 0.10 level and based on the Cochran Q test, with I2 values of 25%,
50%, and 75% representing, respectively, mild, moderate, and extensive statistical
inconsistency.
Fig. 1. Review proﬁle.
Table 2
Key patient and procedural characteristics.
Studies N=30
Patients N=221,066
Age (years) 63 (62; 65)
Male gender 165.800 (75%)
Diabetes 57,035 (26%)
Acute coronary syndrome at admission (including AMI, %) 130,650 (59%)
AMI at admission 44,213 (20%)
Left ventricular ejection fraction at admission (%) 53 (51; 56)
Multivessel disease 81,352 (37%)
Left anterior descending stenting 95,942 (43%)
Implanted device
Bare-metal stent implantation only 4 (13%)
Drug-eluting stent implantation only 15 (50%)
Both bare-metal and drug-eluting stent implantation 12 (37%)
Reported as median (1st; 3rd quartile) or n/N (with patients or studies as denominators,
as appropriate); AMI = acute myocardial infarction.
Table 3
Internal validity of included studies.
Studies N=30
Multivariate analysis approach
Bootstrap 1 (3%)
Conditional logistic regression 5 (17%)
Inclusion of all clinical and angiographic features 9 (33%)
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3.1. Review proﬁle and included studies
From a total of 2095 initial citations, we thoroughly assessed for
eligibility 63 complete reports, after discarding 15 studies enrolling
between 1000 and 2000 patients. From the above 63, 14 citations
were excluded because they did not report on independent predictors
of stent thrombosis [24-37], 12 because of duplicate reporting [2,38-
48], and 7 because of focus on the early and long-term outlook of
stent thrombosis in comparison to ST-elevation myocardial infarction
[4-6,47-50]. Finally, 30 studies were included in the systematic
review, including, 221,066 patients, and 4276 thromboses (Fig. 1,
Online only Table 1, Online only Table 2) [3,7,51-78].
The most important features of these studies are summarized in
Table 1. Brieﬂy, their design was more frequently retrospective
(63%), with a multicenter setting in 63%, and more than two thirds
were conducted in North America or Europe. A median of 4790
patients and 93 stent thromboses were included, with a median
follow-up of 22 months. Patients had a median age of 63 years, 25%
were women, 26% reported diabetes mellitus, and 59% presented at
admission with an ACS (Table 2).
In order to identify independent predictors of stent thrombosis,
several approaches to multivariable analysis were employed by theTable 1
Key features of included studies.
Studies N=30
Study design
Prospective cohort
Retrospective cohort 11 (37%)
Data source
Clinical database 19 (63%)
Post-marketing database 1 (3%)
Year of publication 2009 (2008; 2009)
Setting
Single center 11 (37%)
Multicenter 19 (63%)
Location
Worldwide 1 (3%)
Asia 2 (7%)
North America 10 (33%)
Europe 17 (57%)
Patients undergoing percutaneous coronary stenting 4790 (2069; 7982)
Patients with stent thrombosis 93 (59; 145)
Follow-up (months) 22 (12; 36)
Reported as median (1st; 3rd quartile) or n/N (with studies as denominator).authors of primary studies, but the most frequent was a stepwise
process (43%) with various entry criteria (Table 3). Appraisal of the
internal validity and quality of included studies showed that most of
them were at low risk for analytical, adjudication and attrition bias,
whereas selection bias was clearly more present, as typical of retro-
spective cohort studies focusing on uncommon and ominous events.
In addition, some incomplete reporting was evident, involving in
particular adjudication and attrition details.
3.2. Meta-analysis for the incidence of stent thrombosis
Meta-analytic pooling by means of random-effect methods
yielded a risk of deﬁnite, probable and possible stent thrombosis at
a median of 22 months of 2.4% (2.0%; 2.9%) with 1.5% (1.3%; 1.8%)
for deﬁnite thrombosis (Fig. 2). Acute (b24 h) stent thrombosis oc-
curred in 0.4% (0.2%; 0.6%), deﬁnite subacute thrombosis in 1.0%
(0.8%; 1.2%), deﬁnite late in 0.4% (0.3%; 0.5%), and deﬁnite very late
in 0.5% (0.3%; 0.7%).Propensity score 2 (7%)
Stepwise selection
pb0.05 entry criterion 3 (10%)
pb0.10 entry criterion 7 (23%)
pb0.20 entry criterion 2 (7%)
pb0.25 entry criterion 1 (3%)
Selection bias
Low risk 12 (40%)
Moderate risk 18 (40%)
High or unclear risk 0
Attrition bias
Low risk 15 (50%)
Moderate risk 7 (23%)
High risk 0
Unclear 8 (27%)
Adjudication bias
Low risk 21 (70%)
Moderate risk 6 (20%)
High risk 0
Unclear risk 3 (10%)
Analytical bias
Low risk 18 (60%)
Moderate risk 12 (40%)
High or unclear risk 0
Reported as n/N (with studies as denominator).
Fig. 2. Random-effect pooled estimates of deﬁnite, probable, or possible stent thrombosis (ST) up to a median of 22 months after coronary stenting from all included studies (with
median drug-eluting stenting implantation rate of 95%. Patients (Pts) included and overall stent thromboses are reported in brackets.
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possible stent thrombosis occurred in 3.1% of patients, including def-
inite stent thrombosis in 1.5% (1.3%; 1.8%). The timing of deﬁnite
stent thrombosis in such subset of studies was acute in 0.2% (0.1;
0.2%), subacute in 0.8% (0.7; 0.9%), late in 0.4% (0.3; 0.5%), and very
late in 0.4% (0.2; 0.6%). Graphical inspection of funnel plots did not
disclose evidence of small study bias (e.g. publication bias) for any
of the end-points of interest (Fig. 4).
3.3. Frequency and consistency of stent thrombosis predictors
Despite exploring a total of almost 50 candidate risk factors,
no single predictor was proven universally successful at predicting
stent thrombosis in all included studies, excluding those appraised
in a small subset of studies and thus with limited external validity.
Indeed, the most frequently and consistently reported predictors of
cumulative deﬁnite/probable stent thrombosis were early antiplatelet
therapy discontinuation, extent of coronary disease, and stent number/
length (Fig. 5; Table 4). Acute coronary syndrome at admission, diabetes,Fig. 3. Random-effect pooled estimates of deﬁnite, probable, or possible stent thrombosis (S
included and stent thromboses are reported in brackets.smoking status, and bifurcation/ostial disease also appeared as signiﬁ-
cant predictors, but less consistently.
Appraisal of the most powerful predictors, i.e. those with relative
risk estimates >5 (Fig. 6), singled out antiplatelet therapy discontinu-
ation before 30 days, residual dissection, antiplatelet therapy discon-
tinuation between 30 days and 180 days, stent undersizing, prior
brachytherapy, left ventricular systolic dysfunction, smoking status,
bifurcational/ostial lesion, ACS at admission, and small vessel coronary
disease. However, it must be emphasized that these are not pooled
estimates but estimates from singles studies, and thus at high risk
of small study effects and reporting bias. The complex clustering of
predictors of deﬁnite, deﬁnite or probable, and deﬁnite, probable or
possible stent thrombosis is summarized in Fig. 7.
As an exploratory analysis, we limited our analyses of predic-
tors to large studies (>5000 patients) at low risk of bias [3,6,54,
56,59,67,72,73,76]. In this subsample of 9 studies, including a total
of 153,350 patients and 2495 thromboses, the most common inde-
pendent predictors of deﬁnite or probable stent thrombosis were di-
abetes (reported in 7 out of 9 studies), ACS at admission (5 out of 9),T) up to a median of 22 months after coronary drug-eluting stenting only. Patients (Pts)
Fig. 4. Funnel plot for the cumulative rate of deﬁnite, probable or possible stent
thrombosis.
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tinuation before 30 days (3 out of 9), and extent of coronary disease
(3 out of 9).
4. Discussion
To the best of our knowledge, this is the ﬁrst and only collabora-
tive systematic review focusing on incidence and predictors of stent
thrombosis, aimed at informed clinical decision-making before coro-
nary stenting (i.e. when bypass surgery or medical therapy could
still be preferred), as well as long after stenting. The main ﬁndings
of our work are four-fold: a) stent thrombosis occurs in up to 2.4%
of patients up to 2 years stenting; b) given its ominous implications
[1-11], even such an uncommon event remains a clinical priority;
c) despite a plethora of candidate predictors, risk prognostication in
the individual patient to tailor decision-making remains challenging,
but should best be based on the few prevalent and consistent signiﬁ-
cant predictors hereby identiﬁed: early antiplatelet therapy discon-
tinuation, extent of coronary disease, and stent number/length, as
well as, but to a lesser extent, ACS at admission, diabetes, smoking
status, and bifurcation/ostial disease; d) additional studies exploringFig. 5.Most common predictors of deﬁnite or probable stent thrombosis (i.e. those appraise
ciated with stent thrombosis in most [≥50%] cohorts). ACS = acute coronary syndrome; CA
elevation myocardial infarction.other predictors (e.g. biomarkers) may prove worthwhile, but it is
rather unlikely that any further powerful and common predictor
can be identiﬁed capable of providing additional prognostic ability
on top of the predictors singled out by this systematic review.
Thanks to its comprehensiveness, our study provides evidence
applicable to various clinical scenarios and patients with different
clinical and angiographic features. Indeed, assuming recent estimates
hold true, the patient population included in our meta-analysis
exceeds the number of patients undergoing PCI in any single large
European country yearly. Moreover, in order to provide a real-world
perspective on coronary stenting, we considered studies involving
both BMS and DES [79]. Whereas some cardiologists have advocated
in the past an almost universal adoption of DES, and despite their
evident beneﬁts on restenosis, BMS remain commonly used, especial-
ly in patients less likely to comply with a prolonged dual antiplatelet
regime, and they should not be viewed as obsolete, in Europe as well
as North America [80].
The present analysis was focused on time-related rates of stent
thrombosis. Interestingly subacute and late stent thromboses were
the most frequent events, especially for patients with DES implanta-
tion. Acute stent thrombosis, despite the same ominous impact on
survival [7], is both the less frequently and the less thoroughly ana-
lyzed subtype of thrombosis [81-84]. Similar methodological hurdles
have also limited so far the investigation of very late stent thrombosis
[85,86,87].
None of the 47 candidate predictors of stent thrombosis identiﬁed
in the various studies occurred in all the studies included, reﬂecting
the complex pathophysiology of stent thrombosis, limitations in its
diagnosis and classiﬁcation, its rare occurrence, and the ensuing chal-
lenges in conducting case–control or cohort studies capable of
providing precise, accurate, and consistent statistical results. None-
theless, early antiplatelet therapy discontinuation, extent of coronary
disease, and stent number/length, were commonly and consistently
identiﬁed as predictors of all subtypes of stent thrombosis.
In terms of strength of association, our work cannot provide clear
scientiﬁc evidence in favor or against any predictor, as no formal
meta-analytic pooling was performed focusing on predictors. Howev-
er, extracting data from individual studies suggests that dual antipla-
telet therapy discontinuation may be one of the most powerful
predictors, especially if occurring before 30 days after PCI. The main
drawback of such a statement is however the fact that only a minority
of studies formally tested the independent prognostic role of this pre-
dictor. In addition, information bias (e.g. recall bias) may have played
a role in overestimating the strength of this association. Residual
dissection and stent undersizing were also impacting factors, yetd in at least 5 different studies and being proven independently and signiﬁcantly asso-
D = coronary artery disease; ATD = antiplatelet therapy discontinuation; STEMI = ST-
Table 4
Most commonly reported predictors of stent thrombosis divided by subtype and ordered according to frequency of formal appraisal.
Predictor Formal appraisal
(studies=30;
Pts=221,066)
Any stent thrombosis
(studies=30;
Pts=221,066)
Deﬁnite thrombosis
(studies=8; [2,57,58,62,64,68,
72,73,75-77] Pts=124,967)
Deﬁnite, or probable thrombosis
(studies=20; [2,7,50,51,53,54,56-59,
61-64,68,69,71-77] Pts=199,546)
Diabetes mellitus 23 15 4 12
Acute coronary syndrome at admission 22 15 8 13
Age 22 4 0 4
Total stent number/stent length 17 15 5 12
Hypertension 17 1 0 1
Chronic renal failure 10 6 1 4
Left ventricular systolic dysfunction 10 5 1 3
Prior percutaneous coronary intervention 10 3 1 3
Smoking status 8 4 1 4
Chronic total occlusion 7 2 1 2
Antiplatelet therapy discontinuation (30–180 days) 7 3 1 1
Bifurcation/ostial lesion 6 4 2 3
Restenosis treatment 6 4 2 3
Small vessel coronary disease 6 3 0 2
Antiplatelet therapy discontinuation (b30 days) 5 4 2 4
Extent of coronary artery disease 5 3 1 4
Shock 5 2 1 2
Calciﬁed lesion 5 3 0 2
Paclitaxel-eluting stent implantation 4 3 2 3
Peripheral artery disease 4 2 1 2
Vein graft stenting 4 2 0 2
Left anterior descending stenting 4 1 0 0
Drug-eluting stent implantation 3 2 1 2
Post-procedural TIMI ﬂowb3 3 2 1 2
Residual dissection 3 2 1 2
Congestive heart failure 3 2 0 2
Off-label drug-eluting stent use 3 2 0 2
Cancer 3 1 1 1
Left main disease 3 0 1 1
Prior brachytherapy 3 2 0 1
CYP2C19*2 genotype 2 2 1 1
Stent undersizing 2 1 1 1
Stroke 2 1 1 1
Anemia 2 1 0 1
Prior myocardial infarction 2 1 0 1
Obesity 2 2 0 0
Lesion type 2 1 0 0
Low platelet count 1 1 1 1
SYNTAX score 1 1 1 1
Thrombotic diathesis 1 1 1 1
Black race 1 1 1 1
CYP2C9/A1075C (*1.*3) genotype 1 1 1 1
Post-dilatation 1 1 0 1
Pre-procedural TIMI ﬂowb1 1 1 0 1
Resistance to antiplatelet agents 1 1 0 1
Self-expandable stent implantation 1 1 0 1
Sirolimus-eluting stent implantation 1 1 0 1
Clopidogrel therapy 1 1 0 0
Glycoprotein IIb/IIIa inhibitors 1 1 0 0
CYP2C19 = cytochrome P450 2C19; SYNTAX = SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery; TIMI = Thrombolysis In Myocardial
Infarction.
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ploit this information for risk stratiﬁcation should bear in mind that
some predictors may be very strong in terms of effect, but very rare
(e.g. prior brachytherapy), whereas others might be less potent in
statistical effect, but clinically much more meaningful given their
common occurrence (e.g. diabetes).
These ﬁndings also support a complex and highly multifactorial
model for the pathophysiology of stent thrombosis, without any
single culprit factor, despite being ominous per se, being sufﬁcient
alone to cause stent thrombosis in a sizable portion of patients. In
addition, none of the included studies systematically appraised the
impact of other potentially relevant risk factors, which may play a
hitherto unrecognized role in causing or contributing to stent throm-
bosis, such as strenuous exercise, stress, infections, intercurrent
illness, and bleeding events.
Therefore, stent thrombosis cannot be systematically avoided just
by addressing a single or a few risk factors, but only through a globalappraisal and management of each individual patient. Two frequently
challenging questions will also arise for physicians managing patients
with stent who require non-cardiac surgery or those with atrial ﬁbril-
lation. It has been recently demonstrated that subjects undergoing
non-cardiac surgery are less likely to take aspirin and clopidogrel,
and are at higher risk of thrombotic events [89]. Moreover, recent
consensus statements on atrial ﬁbrillation [90,91] have provided
important yet controversial recommendations on stent implantation
and antithrombotic therapy in these patients. To correctly manage
these patients, it becomes fundamental to individually risk-stratify
the patient before and after PCI in terms of both thrombotic and
bleeding risk, and choose the most appropriate management strategy.
Accordingly, an explicit choice between amore aggressive antiplatelet
therapy with prasugrel, ticagrelor or glycoprotein IIb/IIIa inhibitors, or
a less invasive strategy with implantation of BMS could be envisioned
[15]. Important insights will be provided also by studies focusing on
high residual platelet reactivity as a marker of the risk of stent
Fig. 6.Most powerful predictors of deﬁnite or probable stent thrombosis from individual included studies (i.e. those associated with a relative estimate of risk >5.0 or b0.2 for stent
thrombosis). ACS = acute coronary syndrome; ATD = antiplatelet therapy discontinuation; CAD = coronary artery disease; STEMI = ST-elevation myocardial infarction.
581F. D'Ascenzo et al. / International Journal of Cardiology 167 (2013) 575–584thrombosis [45]. This holds even truer for patients who have already
experienced a stent thrombosis and in whom medical therapy must
be aptly chosen and maximized to avoid recurrences. Indeed, we ap-
praised formally the association between stent thrombosis and resis-
tance to antiplatelet agents and found that speciﬁc genotypes
associated with resistance to antiplatelet agents and resistance to
antiplatelet agents itself as measured by platelet function assay was
associated with stent thrombosis in a subset of studies. Whether this
apparently limited association after multivariable adjustment be-
tween resistance to antiplatelet agents and stent thrombosis is due
to selective reporting or publication bias requires additional research
[92].
Notably, age, lesion subtype, renal failure, diabetes mellitus, and
ejection fraction, as well as many others, are all very important pre-
dictive factors and would require detailed analyses. Indeed, we
reported that they all were, albeit with variable consistency, associat-
ed with stent thrombosis, thus conﬁrming even in our work their
important prognostic impact. However, additional analyses wereFig. 7. Venn diagram synthesizing the most common predictors of stent thrombosis
(i.e. those present in at least 10% of included studies), according to Academic Research
Consortium deﬁnitions. ATD = antiplatelet therapy discontinuation; CAD = coronary
artery disease; CHF = congestive heart failure; CRF = chronic renal failure; CTO =
chronic total occlusion; DES = drug-eluting stent; DM = diabetes mellitus; LVEF =
left ventricular ejection fraction; PES = paclitaxel-eluting stent; PLT = platelets; LM =
left main disease; PAD = peripheral artery disease; PCI = percutaneous coronary inter-
vention; TIMI = Thrombolysis In Myocardial Infarction ﬂow.beyond the scope of our work. Indeed, deﬁnitions of these variables
were different among the included studies, thus limiting the room
for a careful and detailed analysis. In addition, a spectrum of severity
can be envisioned for any of these variables, with important prognos-
tic implications. For instance, we typically dichotomize bifurcation
lesions as being present or absent. However, true bifurcations have
a larger prognostic impact of pseudobifurcations, and the same ap-
plies to proximal bifurcations versus distal bifurcations, and to trifur-
cations compared to bifurcations with only one side branch [93].
The same applies to age, diabetes mellitus, renal failure, and systolic
dysfunction, as well as to many other variables, which are often di-
chotomized, but more realistically present with a very large spectrum
of values.
It has also been reported that statins, post-dilation and stent
length can impact on both early and late events. Indeed, by study
design, we were theoretically able to capture and appraise the prog-
nostic role of any of these factors, as long as they were consistently
reported in short-listed studies. We did conﬁrm the association be-
tween stent length and stent thrombosis, and, to a lesser extent, the
association between post-dilation and stent thrombosis. However,
we did not ﬁnd consistent data in support of the protective role of
statins for stent thrombosis. However, as for stent type, our review
was not adequately powered to establish the protective role of drug
therapy, which is best tested by randomized clinical trials.
Finally, biomarkers in general and natriuretic peptides in particu-
lar have been proposed as potential predictors of stent thrombosis.
We found however limited data in support of the prognostic role of
any biomarker as far as stent thrombosis is concerned. However,
there is evidence, albeit limited, that C-reactive protein can predict
stent thrombosis [94]. Conversely, no study so far has suggested an
association between natriuretic peptides and stent thrombosis.
However, this by no means invalidates the pivotal prognostic role of
natriuretic peptides across the spectrum of cardiovascular conditions.
4.1. Limitations
This work has several major drawbacks [95]. First, we focused on a
rare event, fraught with the risk of selective reporting, and thus ex-
cluded 15 studies enrolling between 1000 and 1999 patients, which
would have provided potentially biased estimates at multivariable
analysis [21]. Second, we did not perform a pooled analysis of risk
predictors, because this would have been limited by substantial
reporting bias. Third, we focused on predictors of cumulative stent
thrombosis but did not explore in details predictors of thrombosis
582 F. D'Ascenzo et al. / International Journal of Cardiology 167 (2013) 575–584at different times. Fourth, we included studies with a mixture of DES
and BMS, often chosen at the discretion of the operator, with stent
choice being most likely driven by several and complex confounders.
Thus, the ﬁnding that DES did not prove consistently a predictor of
stent thrombosis, should be viewed with caution, even if it appears
in agreement with prior observational, randomized and meta-
analytic studies. Peri-procedural events, including iatrogenic compli-
cations (e.g. plaque prolapse, plaque embolization, snow plough
effect and dissection) [88], and ensuing increases in cardiac bio-
markers [96] have very important implications in general and in caus-
ing subsequent stent thrombosis. However, focusing on such events
in detail, as well as on ECG data, was beyond the scope of our work.
Moreover, publication bias remains always a concern because the
present review was based solely on published studies, yet small
study bias was not apparent at funnel plot inspection. Most predictors
were appraised in only a subset of studies, limiting the precise quan-
titative estimation of their independent predictive role. Another lim-
itation, most likely the greatest one, of this review is the study-level
setting, thus lacking the precision and ﬂexibility of a patient-level
work, which would have enabled more detailed analyses trying to
disentangle the complex interplay between confounding factors, pre-
dictors, and events. Indeed, individual patient data would have pro-
vided more detailed information on incidence and predictors, but
most likely would have required exclusion of several datasets, thus
limiting unduly the external validity of the analyses [97]. Moreover,
patient-level and study-level meta-analyses are often in agreement
[98], and thus our ﬁndings should be consistent with future patient-
level works on this topic. In addition, diagnostic criteria and deﬁni-
tions of stent thrombosis have changed over time, and these changes
may have introduced the risk of information bias. Finally, we aimed
to provide a comprehensive synthesis of potentially useful clinical
predictors of stent thrombosis, to guide invasive and non-invasive
cardiologists in their everyday risk-prognostication effort, but not
challenge predictors with established role in this setting such as dura-
tion of dual antiplatelet therapy and stent type [51,69]. Only existing
or future randomized trials of such medical interventions can inform
on their risk–beneﬁt balance in preventing stent thrombosis.
5. Conclusions
Despite numerous possible risk factors, the most common and
consistent predictors of stent thrombosis are early antiplatelet thera-
py discontinuation, extent of coronary disease, and stent number/
length. Knowledge of these risk factors is essential to inform appro-
priate clinical decision making when considering the risks versus
beneﬁts or coronary stents.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.ijcard.2012.01.080.
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